Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
44
ORKA Quote, Financials, Valuation and Earnings
Last price:
$15.38
Seasonality move
:
-11.9%
Day range:
$14.03 - $14.85
52-week range:
$5.49 - $52.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.53x
Volume:
100.1K
Avg. volume:
288K
1-year change:
-65.26%
Market cap:
$554.1M
Revenue:
--
EPS (TTM):
-$2.86
Analysts' Opinion
-
Consensus RatingOruka Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $39.50, Oruka Therapeutics has an estimated upside of 166.89% from its current price of $14.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing -1.35% downside risk from its current price of $14.80.
Fair Value
-
According to the consensus of 7 analysts, Oruka Therapeutics has 166.89% upside to fair value with a price target of $39.50 per share.
ORKA vs. S&P 500
-
Over the past 5 trading days, Oruka Therapeutics has overperformed the S&P 500 by 3.94% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Oruka Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Oruka Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Oruka Therapeutics reported revenues of --.
Earnings Growth
-
Oruka Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Oruka Therapeutics reported earnings per share of -$0.40.
Enterprise value:
208M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -$82.9M | -$6.9M | -$25.1M | |
| EBITDA | -- | -- | -$77.5M | -$6.9M | -$21M | |
| Diluted EPS | -- | -- | -$2.86 | -$0.24 | -$0.40 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $27.7M | $352.1M | |
| Total Assets | -- | -- | -- | $28.2M | $377.1M | |
| Current Liabilities | -- | -- | -- | $7.2M | $11.7M | |
| Total Liabilities | -- | -- | -- | $35.3M | $12.4M | |
| Total Equity | -- | -- | -- | -$7.1M | $364.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$168K | -$20.9M | |
| Cash From Investing | -- | -- | -- | -- | $42.9M | |
| Cash From Financing | -- | -- | -- | $27.9M | -- | |
| Free Cash Flow | -- | -- | -- | -$168K | -$20.9M | |
ORKA
Sector
Market Cap
$554.1M
$34.4M
Price % of 52-Week High
28.29%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-65.26%
-37.36%
Beta (5-Year)
-0.343
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.12
200-day SMA
Sell
Level
$15.88
Bollinger Bands (100)
Buy
Level
9.32 - 12.58
Chaikin Money Flow
Sell
Level
-5.7M
20-day SMA
Buy
Level
$12.69
Relative Strength Index (RSI14)
Buy
Level
69.15
ADX Line
Buy
Level
26.99
Williams %R
Sell
Level
-7.4571
50-day SMA
Buy
Level
$11.72
MACD (12, 26)
Buy
Level
0.81
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
9.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Stock Forecast FAQ
In the current month, ORKA has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ORKA average analyst price target in the past 3 months is $39.50.
-
Where Will Oruka Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Oruka Therapeutics share price will rise to $39.50 per share over the next 12 months.
-
What Do Analysts Say About Oruka Therapeutics?
Analysts are divided on their view about Oruka Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Oruka Therapeutics is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Oruka Therapeutics's Price Target?
The price target for Oruka Therapeutics over the next 1-year time period is forecast to be $39.50 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ORKA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Oruka Therapeutics is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ORKA?
You can purchase shares of Oruka Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Oruka Therapeutics shares.
-
What Is The Oruka Therapeutics Share Price Today?
Oruka Therapeutics was last trading at $15.38 per share. This represents the most recent stock quote for Oruka Therapeutics. Yesterday, Oruka Therapeutics closed at $14.80 per share.
-
How To Buy Oruka Therapeutics Stock Online?
In order to purchase Oruka Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
